TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Physical Self-Esteem (PSE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraoperative ventilatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial blood gas determinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total operating time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: emotional support and positive reframing scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: planning and active coping scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adipose tissue NF-κB activity decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved erectile function (IIEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved emotional well-being (SEAR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Greater treatment satisfaction (EDITS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient preference for chewing gum treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: onset time to maximal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration from maximal block to 25% recovery of TOF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversal time to 75% of TOF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fixations on GHWs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetes and cardiovascular-related morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of MRSA carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Brivanib exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary silicon level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expertise of the doctor
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: thoroughness of consultation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Total colonoscopy achieved without sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: monthly tumor recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade I-V complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Deep vein thrombosis (DVT) rate at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Effectiveness of CPAP in treating sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure required for CPAP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: 6-year disease-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Aqueous humor flow increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: GH production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SC50 for GH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Grading of the difficulty of CC GW crossing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C target achievement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient pain during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence density of nosocomial infections
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation of assigned treatment
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of cervical activated (HLA‐DR+CD38+) CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Placebo-related anxiety symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of exception from informed consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biomarkers of weight maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asymmetry parameters of postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to 75% healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic effect in the first 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected near visual acuity (UNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative anterior laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: instrumented laxity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year event-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Enamel rehardening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of self-reported opioid withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S(HV)O2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximal percentage change from baseline in TPVR:SVR ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Foot Function Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treated tic frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of maximal force of knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POMS-Total Mood Disturbance (TMD) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anger-hostility mood state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: POMS iceberg profile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wake after sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep architecture (stage 1, stage 2, slow wave sleep, REM sleep)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Course attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adequacy of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of pterygia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-score on NSAID side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival free of death or need for cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Renal flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression to end-stage renal disease (ESRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: overall episodic heartburn relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VHI-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GRBAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alloimmunization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: lean soft tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained reversal of MS-related disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of parenteral nutrition‐associated cholestasis (PNAC)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of necrotizing enterocolitis (NEC) ≥ stage II
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days required to achieve full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in signs and symptoms over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver TID values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Liver wash-in values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Agoraphobic behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-management behaviors
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: unplanned HSU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage time when glucose was in the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall implant survival and success rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean DMFT increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean DMFS increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of achieving meaningful pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects from medication
Endpoint domain: Adverse events/effects
Primary endpoint: Antibacterial effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improved stiffness of facial skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's past year experience of physical IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Men's perpetration of IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between raters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of medications for IOP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP provoked AF or atrial ectopic beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference between groups for primary outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tolerate a general diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Onset of bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Passage of first bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response to treatment with SSZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Steady-state concentration of analytes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose proportionality constant (β) for AUCss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma FGF21 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy expenditure during cold exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intrusive thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAR abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative PCA dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with GTVL below the lower limit of quantification (LLQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Societal cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accumulated difference in QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cost/QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative parenteral opiate requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Time to clip the cystic duct after cholangiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to place the cannulas after skin incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: self-reported use of soap or sanitizer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-reported frequency of hand washing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptoms of hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in smoking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node recurrence (LRF)
Endpoint domain: Mortality/survival
Primary endpoint: Adverse clinical events (ACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in periodontitis‐associated bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative attachment level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived treatment discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C(max) of desisobutyryl ciclesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) of desisobutyryl ciclesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivational readiness for regular physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggravation of gastritis in the corpus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Partial elimination of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of inflammation in the antrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative QoL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total score of the PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TG, BMI, and HDL-c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time required for tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: self-efficacy for arthritis symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with general health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Development of symptoms in celiac disease patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all SAD measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-hour peak GH rebound after somatostatin infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean (150 min) maximal GH rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: distributive risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in expressive aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in risk-taking behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Compound A in inspiratory gas mix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum fluoride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean half-life of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean half-life of alfentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adherence to health management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with Ramsay sedation score of 4 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of HCV at-risk practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of associated cutaneous complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in HCV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reducing methamphetamine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retaining patients in treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: reducing methamphetamine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of MFSN in the treatment of AR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of locoregional lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in futile surgery
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year locoregional control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold-induced wheal reaction delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal response at 3 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal response at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ABT-122 compared to adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant oxygen desaturation event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of airway assist maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: referral quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portion sizes of high-fat foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of coping planning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VISA-P score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violent attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: locus of control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily average weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time needed for wound care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes